Literature DB >> 15456875

Genetically increasing Myoc expression supports a necessary pathologic role of abnormal proteins in glaucoma.

Douglas B Gould1, Laura Miceli-Libby, Olga V Savinova, Mario Torrado, Stanislav I Tomarev, Richard S Smith, Simon W M John.   

Abstract

Despite the importance of MYOC for glaucoma, the protein's normal function(s) and the pathogenic mechanism(s) of MYOC mutations are not clear. Elevated intraocular pressure (IOP) and glaucoma are sometimes induced by corticosteroids, and corticosteroid use can result in substantially increased MYOC expression. It has been suggested, therefore, that steroid-induced MYOC protein levels cause steroid-induced glaucoma and that protein level-increasing mutations in MYOC contribute to glaucoma not associated with steroid use. A causative role of elevated MYOC levels in steroid-induced glaucoma is controversial, however, and it is not clear if elevated MYOC levels can result in IOP elevation. To directly test if increased levels of MYOC can cause IOP elevation and glaucoma, we generated bacterial artificial chromosome transgenic mice that overexpress Myoc at a level similar to that induced by corticosteroid use. These mice do not develop elevated IOP or glaucoma. Our present findings, along with the absence of glaucoma in mice completely lacking MYOC, show that changing the level of MYOC is not pathogenic (from absent to approximately 15 times normal). These findings suggest that noncoding sequence variants are unlikely to influence glaucoma and that disease pathogenesis in primary open-angle glaucoma patients is dependent upon the expression of abnormal mutant proteins. This work does not support a causative role for increased MYOC levels or the MYOC gene in steroid-induced glaucoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15456875      PMCID: PMC517885          DOI: 10.1128/MCB.24.20.9019-9025.2004

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  47 in total

1.  GLC1F, a new primary open-angle glaucoma locus, maps to 7q35-q36.

Authors:  M K Wirtz; J R Samples; K Rust; J Lie; L Nordling; K Schilling; T S Acott; P L Kramer
Journal:  Arch Ophthalmol       Date:  1999-02

2.  Glucocorticoid induction of the glaucoma gene MYOC in human and monkey trabecular meshwork cells and tissues.

Authors:  A F Clark; H T Steely; J E Dickerson; S English-Wright; K Stropki; M D McCartney; N Jacobson; A R Shepard; J I Clark; H Matsushima; E R Peskind; J B Leverenz; C W Wilkinson; R E Swiderski; J H Fingert; V C Sheffield; E M Stone
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-07       Impact factor: 4.799

3.  Delayed secondary glucocorticoid responsiveness of MYOC in human trabecular meshwork cells.

Authors:  A R Shepard; N Jacobson; J H Fingert; E M Stone; V C Sheffield; A F Clark
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-12       Impact factor: 4.799

4.  Changes in mRNA levels of the Myoc/Tigr gene in the rat eye after experimental elevation of intraocular pressure or optic nerve transection.

Authors:  F Ahmed; M Torrado; E Johnson; J Morrison; S I Tomarev
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-12       Impact factor: 4.799

5.  Apolipoprotein E-promoter single-nucleotide polymorphisms affect the phenotype of primary open-angle glaucoma and demonstrate interaction with the myocilin gene.

Authors:  Bruno Copin; Antoine P Brézin; Françoise Valtot; Jean-Claude Dascotte; Alain Béchetoille; Henri-Jean Garchon
Journal:  Am J Hum Genet       Date:  2002-05-03       Impact factor: 11.025

6.  Effects of elevated intraocular pressure on outflow facility and TIGR/MYOC expression in perfused human anterior segments.

Authors:  Teresa Borrás; Laura Leigh S Rowlette; Ernst R Tamm; Johannes Gottanka; David L Epstein
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-01       Impact factor: 4.799

7.  Molecular and clinical evaluation of a patient hemizygous for TIGR/MYOC.

Authors:  J L Wiggs; D Vollrath
Journal:  Arch Ophthalmol       Date:  2001-11

8.  Targeted Disruption of the Myocilin Gene (Myoc) Suggests that Human Glaucoma-Causing Mutations Are Gain of Function.

Authors:  B S Kim; O V Savinova; M V Reedy; J Martin; Y Lun; L Gan; R S Smith; S I Tomarev; S W John; R L Johnson
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

9.  TIGR/MYOC gene sequence alterations in individuals with and without primary open-angle glaucoma.

Authors:  Chi Pui Pang; Yuk Fai Leung; Baojian Fan; Larry Baum; Win Chi Tong; Wing Shan Lee; John K H Chua; Dorothy S P Fan; Yao Liu; Dennis S C Lam
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-10       Impact factor: 4.799

10.  Variations in the myocilin gene in patients with open-angle glaucoma.

Authors:  Wallace L M Alward; Young H Kwon; Cheryl L Khanna; A Tim Johnson; Sohan S Hayreh; M Bridget Zimmerman; Joanna Narkiewicz; Jeaneen L Andorf; Paula A Moore; John H Fingert; Val C Sheffield; Edwin M Stone
Journal:  Arch Ophthalmol       Date:  2002-09
View more
  55 in total

1.  Aggregated myocilin induces russell bodies and causes apoptosis: implications for the pathogenesis of myocilin-caused primary open-angle glaucoma.

Authors:  Gary Hin-Fai Yam; Katarina Gaplovska-Kysela; Christian Zuber; Jürgen Roth
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 2.  Glaucoma-associated myocilin: a better understanding but much more to learn.

Authors:  Zachary T Resch; Michael P Fautsch
Journal:  Exp Eye Res       Date:  2008-08-29       Impact factor: 3.467

3.  Myocilin regulates cell proliferation and survival.

Authors:  Myung Kuk Joe; Heung Sun Kwon; Radu Cojocaru; Stanislav I Tomarev
Journal:  J Biol Chem       Date:  2014-02-22       Impact factor: 5.157

4.  Myocilin interacts with syntrophins and is member of dystrophin-associated protein complex.

Authors:  Myung Kuk Joe; Changwon Kee; Stanislav I Tomarev
Journal:  J Biol Chem       Date:  2012-02-25       Impact factor: 5.157

Review 5.  Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine.

Authors:  M Elizabeth Fini; Stephen G Schwartz; Xiaoyi Gao; Shinwu Jeong; Nitin Patel; Tatsuo Itakura; Marianne O Price; Francis W Price; Rohit Varma; W Daniel Stamer
Journal:  Prog Retin Eye Res       Date:  2016-09-22       Impact factor: 21.198

6.  Triamcinolone acetonide decreases outflow facility in C57BL/6 mouse eyes.

Authors:  Sandeep Kumar; Shaily Shah; Emily Rose Deutsch; Hai Michael Tang; John Danias
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-01       Impact factor: 4.799

7.  Immunohistochemical evaluation of the extracellular matrix in trabecular meshwork in steroid-induced glaucoma.

Authors:  Akihiko Tawara; Norihiko Tou; Toshiaki Kubota; Yukinori Harada; Kiyomi Yokota
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-02       Impact factor: 3.117

8.  Myocilin is a modulator of Wnt signaling.

Authors:  Heung-Sun Kwon; Hee-Sheung Lee; Yun Ji; Jeffrey S Rubin; Stanislav I Tomarev
Journal:  Mol Cell Biol       Date:  2009-02-02       Impact factor: 4.272

9.  Little evidence for association of the glaucoma gene MYOC with open-angle glaucoma.

Authors:  Seongsoo Sohn; Wonhee Hur; Young Ran Choi; Yun Shin Chung; Chang-Seok Ki; Changwon Kee
Journal:  Br J Ophthalmol       Date:  2010-05       Impact factor: 4.638

10.  RNA interference as a gene silencing therapy for mutant MYOC protein in primary open angle glaucoma.

Authors:  Mao Li; Jianjiang Xu; Xueli Chen; Xinghuai Sun
Journal:  Diagn Pathol       Date:  2009-12-16       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.